J&J’s EPO Franchise Takes A Hit From Regulatory Scrutiny
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the erythropoiesis-stimulating agent Procrit plunged 14 percent in the second quarter, causing J&J to revise sales expectations.
You may also be interested in...
Johnson & Johnson Tightens Organization To Find Savings
To save $1.3 billion to $1.6 billion a year, J&J is cutting 4,000 to 5,000 jobs in its pharma and Cordis segments and consolidating the Cordis franchise.
Johnson & Johnson Tightens Organization To Find Savings
To save $1.3 billion to $1.6 billion a year, J&J is cutting 4,000 to 5,000 jobs in its pharma and Cordis segments and consolidating the Cordis franchise.
J&J’s HIV Therapy Etravirine Shown To Have Antiviral Activity In Phase III Studies
Two Phase III trials found significantly more patients taking the non-nucleoside reverse transcriptase inhibitor reached undetectable viral load.